

October 29, 2024

BSE Limited Phiroze Jeejeebhai Towers, Dalal Street, Mumbai – 400001 Scrip Code – 526783

Dear Sir/ Madam,

Subject: Outcome of Board Meeting

Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, we wish to inform you that the Board of Directors at their meeting held today, i.e., Tuesday, October 29, 2024, inter-alia approved the following:

1. Unaudited Financial Results:

Unaudited financial results along with limited review report from the statutory auditors for the quarter and half year ended September 30, 2024.

Further, the financial results will be published in the newspaper in compliance with Regulation 47 of SEBI (LODR) Regulations, 2015. The financial results will also be available on the website of the Company – www.dragarwal.com. A copy of the extracts of the results to be published is enclosed.

2. Interim Dividend:

Declaration of interim dividend of INR 2.50 (Rupees Two and Fifty Paise) per equity share of INR 10 each fully paid-up (25%) for the financial year 2024-25.

As intimated earlier vide letter dated October 24, 2024 and pursuant to Regulation 42 of SEBI (LODR) Regulations, 2015, the record date for payment of interim dividend shall be November 08, 2024. The interim dividend shall be paid/dividend warrant/demand draft shall be dispatched to the Members on or before November 25, 2024.

3. Appointment of Interim Chief Financial Officer:

Appointment of Mr. Yashwanth Venkat, Chief Financial Officer of Dr. Agarwal's Health Care Limited (Holding Company), as the Interim Chief Financial Officer and Key Managerial Personnel of the Company, pursuant to provisions of Section 203 of the Companies Act, 2013, with effect from October 29, 2024, till the time a new Chief Financial Officer is appointed by the Board of Directors. The details as required under the Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, is enclosed as Annexure I.

4. Closure of Operations in Neyveli Branch:

Closure of operations in the Neyveli branch. It does not have any material and adverse effect on operations of the Company. The details required pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015 and SEBI Circular No SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are given below:

Dr. Agarwal's Eye Hospital Limited



Details	Particulars
Date of such binding agreement, if	Not Applicable
any, entered for sale of such unit/division, if any	
Amount and percentage of turnover or revenue or income and net worth of the listed entity contributed by such unit or division during the last financial year	
Date of closure or estimated time of closure	On or before April 30, 2025
Reasons for Closure	The Company is already operating a larger facility in Virudhachalam to cater the needs in that region. The Board has, after careful consideration and assessment of operations of the Neyveli branch, concluded that there is insufficient/ insignificant value addition in operating the said branch.

5. Reconstitution of the Committees of the Board:

i. Pursuant to Section 177 of the Companies Act, 2013 read with Regulation 18 of the SEBI (LODR) Regulations, 2015, the Board of Directors have reconstituted the Audit Committee of the Board of Directors as under:

S. No	Name of the Member	Designation in the Committee
1.	Venkatraman Balakrishnan	Chairperson, Independent Director
2.	Latha Ramanathan	Member, Independent Director
3.	Shiv Agrawal	Member, Independent Director
4.	Dr. Adil Agarwal	Member, Non-Executive Director

ii. Pursuant to Section 178 of the Companies Act, 2013 read with Regulation 19 of the SEBI (LODR) Regulations, 2015, the Board of Directors have reconstituted the Nomination and Remuneration Committee of the Board of Directors as under:

S. No	Name of the Member	Designation in the Committee			
1.	Shiv Agrawal	Chairperson, Independent Director			
2.	Venkatraman Balakrishnan	Member, Independent Director			
3.	Latha Ramanathan	Member, Independent Director			
4.	Dr. Adil Agarwal	Member, Non-Executive Director			



iii. Pursuant to Section 178 of the Companies Act, 2013 read with Regulation 20 of the SEBI (LODR) Regulations, 2015, the Board of Directors have reconstituted the Stakeholder Relationship Committee of the Board of Directors as under:

S. No	Name of the Member	Designation in the Committee				
1.	Dr. Adil Agarwal	Chairperson, Non-Executive				
		Non- Independent Director				
2.	Shiv Agrawal	Member, Independent Director				
3.	Venkatraman Balakrishnan	Member, Independent Director				
4.	Latha Ramanathan	Member, Independent Director				

iv. Pursuant to Section 135 of the Companies Act, 2013, Board of Directors have reconstituted the Corporate Social Responsibility of the Board of Directors as under:

S. No	Name of the Member	Designation in the Committee
1.	Dr. Athiya Agarwal	Chairperson, Whole-time Director
2.	Dr. Amar Agarwal	Member, Whole-time Director
3.	Latha Ramanathan	Member, Independent Director
4.	Shiv Agrawal	Member, Independent Director

6. Postal ballot notice:

Postal Ballot Notice to seek the approval of the shareholders for appointment of Mr. Shiv Agrawal (DIN: 00040199) as an Independent Director for a term of five years from September 06, 2024 to September 05, 2029.

Postal Ballot Notice shall be sent in due course to all the shareholders whose names appear on the Register of Members / list of Beneficial Owners as received from National Securities Depository Limited (NSDL) / Central Depository Services (India) Limited (CDSL) as on Thursday, October 31, 2024 ("Cut-off date") and who have registered their email id with the Company / Depository Participants and the same shall be filed with the Stock Exchange.

The meeting commenced at 04:30 pm and concluded at 06:50 pm.

Yours truly For **Dr. Agarwal's Eye Hospital Limited**

Meenakshi Jayaraman Company Secretary & Compliance Officer



Annexure I – Details as required under the Regulation 30 of the SEBI (LODR) Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

S. No	Particulars	Details
1.	Name	Mr. Yashwanth Venkat
2.	Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment as the Interim Chief Financial Officer
3.	Date of appointment/ cessation (as applicable) & term of appointment	October 29, 2024
4.	Brief profile (in case of appointment)	Mr. Yashwanth Venkat is currently the Chief Financial Officer of Dr. Agarwal's Health Care Limited (Holding Company). He joined the Group on May 18, 2018 and served as the Vice-President – Business Finance and M&A until his appointment as the Chief Financial Officer of the Holding Company. He holds a bachelor's degree in chemical engineering from Anna University. He holds a post graduate diploma in management from IIM Bangalore. Prior to joining our group, Mr. Yashwanth Venkat was handling various roles with IBM India Private Limited, Murugappa Management Services Limited, Intellect Design Arena Limited, Scope International Private Limited, Cognizant Technology Solutions India Private Ltd. and VA Tech Wabag Limited. He has over 14 years of experience in the field of finance and accounts.
5.	Disclosure of relationships between directors (in case of appointment of a director).	Nil

Deloitte Haskins & Sells

Chartered Accountants ASV N Ramana Tower 52, Venkatnarayana Road T. Nagar Chennai - 600 017 Tamil Nadu, India

Tel: +91 44 6688 5000 Fax: +91 44 6688 5050

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF DR. AGARWAL'S EYE HOSPITAL LIMITED

- 1. We have reviewed the accompanying Statement of Unaudited Financial Results of **DR. AGARWAL'S EYE HOSPITAL LIMITED** ("the Company"), for the quarter and six months ended 30 September 2024 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS**

Chartered Accountants (Firm's Registration No. 008072S)

R. Prosance

R. Prasanna Venkatesh (Partner)

(Membership No. 214045)

Place: Chennai

Date: 29 October 2024

UDIN: 24214045BKEKMN9450

Dr Agarwals Ege Hospital

Dr. Agarwal's Eye Hospital Limited
CIN: L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No.4, Moores Road, Off Greams Road, Chennai - 600 006
Phone No. 91-44-43787777 Website: www.dragarwal.com E-mail: investor@dragarwal.com

						(Amount in IN	R Crores except EPS)
	Statement of Unaudited Financial Results fo	r the Quarter and Si	x Months Ended 30	Oth September 2024	4		
S.No.	Particulars	30-Sep-24 (Unaudited)	Quarter Ended 30-Jun-24 (Unaudited)	30-Sep-23 (Unaudited)	Six Month 30-Sep-24 (Unaudited)	s Ended 30-Sep-23 (Unaudited)	Year Ended 31-Mar-24 (Audited)
1	Income	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	((5.1.2.2.1.7)		(3	(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
	(a) Revenue from Operations	102,19	100.02	84.09	202,21	162.64	319.30
	(b) Other Income	2,28	0.40	1,47	2.68	1.83	4.97
	Total Income	104.47	100.42	85.56	204.89	164,47	324.27
2	Expenses						
	(a) Purchase of Stock-in-Trade	9.07	11.56	9.93	23,19	18,42	35,95
	(b) Changes in Inventories of Stock-in-Trade - (Increase) / Decrease	1.88	(1.41)	(0,44)	(2.09)	(1.07)	(2,25
	(c) Surgical Lens including other consumables	12,95	11,89	9,72	24.84	18.29	36.85
	(d) Consultancy Charges for Doctors	13.53	14.24	13,50	27.77	24,71	48.37
	(e) Employee Benefits Expenses	19,90	17.57	16.43	37.47	32,86	63.78
	(f) Finance Costs	3,67	3.03	1.69	6.70	3,31	7.1
	(g) Depreciation and Amortisation Expense	9,36	9,87	6,34	19,23	12,19	26.6
	(h) Other Expenses	14.98	14.76	11.74	29.74	23,57	45.54
	Total Expenses	85.34	81.51	68.91	166.85	132.28	262.02
3	Profit before tax (1-2)	19.13	18.91	16.65	38.04	32.19	62.25
4	Tax Expense						
	- Current Tax	4.73	5.21	3,97	9.94	8.14	16.22
	- Deferred Tax (Net)	0.25	(0.41)	0,09	(0.16)	(0.08)	(0.3
5	Net Profit after tax for the period / year (3-4)	14.15	14.11	12.59	28.26	24.13	46.36
6	Other Comprehensive Income						
	Items that will not be reclassified to the Statement of Profit and Loss				0.00		
	- Actuarial (loss) / gain on defined benefit obligation	(0.28)	0,03	(0.53)	(0.25)	(0.65)	0.08
	Tax on items that will not be reclassified to the Statement of Profit and Loss	0.07	(0.01)	0_14	0.06	0.17	(0.01
	Total Other Comprehensive income / (loss) (net of tax)	(0.21)	0.02	(0.39)	(0.19)	(0,48)	0.04
7	Total Comprehensive Income / (Loss) (5+6)	13.94	14.13	12.20	28.07	23.65	46.40
3	Paid-up equity share capital (Face value INR 10/- each)	4.70	4.70	4.70	4.70	4.70	4,70
9	Reserves (Other Equity)	1 1					152.45
0	Earnings Per Equity Share (EPS) (Face value of INR 10/- each)						
	(a) Basic	30.11	30.02	26.79	60,13	51.34	98.64
	(b) Diluted	30.11	30.02	26.79	60.13	51.34	98.64
		(not Annualised)	(not Annualised)	(not Annualised)	(not Annualised)	(not Annualised)	(Annualised





Dr. Agarwal's Eye Hospital Limited
CIN: L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No.4, Moores Road, Off Greams Road, Chennai - 600 006 Phone No. 91-44-43787777 Website: www.dragarwal.com E-mail: investor@dragarwal.com

	D.I 01		(Amount in INR Crores)
-	Balance Sh	ieet	
S.No	Particulars	As at 30th September 2024 Unaudited	As at 31st March 2024 Audited
Α	ASSETS	Unaudited	Audited
1	Non-Current Assets		
•	(a) Property, Plant and Equipment	137.06	120.87
	(b) Right to Use Assets	200.57	193.96
	(c) Capital Work-In-Progress	113.66	97.44
	(d) Goodwill	5.66	0.18
	(e) Other Intangible Assets	20.42	0.62
	(f) Financial Assets		
	(i) Other Financial Assets	8.84	8.50
	(g) Deferred Tax Assets (Net)	10.25	10.03
	(h) Other Non-Current Assets	11.42	4.33
	Total Non-Current Assets	507.88	435.93
2	Current Assets		
	(a) Inventories (b) Financial Assets	11.80	9.75
	(i) Investments	13.49	*
	(ii) Trade Receivables	16.25	12.93
	(iii) Cash and Cash Equivalents	14.15	32.88
	(iv) Bank Balances other than Cash and Cash Equivalents	0.81	0.86
	(v) Other Financial Assets	2.49	1.96
	(c) Other Current Assets	1.96	1.45
	Total Current Assets	60.95	59.83
	Total Assets(1+2)	568.83	495.76
- 1	EQUITY AND LIABILITIES EQUITY		
٦		4.70	4.70
	(a) Equity Share Capital (b) Other Equity	179.34	152.45
	Total Equity	184.04	157.15
	LIABILITIES		
4	Non-Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	66.89	44.46
	(ia) Lease Liabilities	214.27	203.59
	(ii) Other Financial Liabilities	8.90	2.36
	(b) Provisions	8.55	7.43
	Total Non-Current Liabilities	298.61	257.84





Dr. Agarwal's Eye Hospital Limited CIN: L85110TN1994PLC027366

Dr Agarwals

Eye Hospital

Regd Office: 3rd Floor, Buhari Towers, No.4, Moores Road, Off Greams Road, Chennai - 600 006 Phone No. 91-44-43787777 Website: www.dragarwal.com E-mail: investor@dragarwal.com

(Amount in INR Crores)

Balance Sheet				
S.No	Particulars	As at 30th September 2024 Unaudited	As at 31st March 2024 Audited	
5	Current Liabilities			
	(a) Financial Liabilities (i) Borrowings	10.67	6.84	
	(ia) Lease Liabilities (ii) Trade Payables	13.33	13.13	
	 Total outstanding dues of micro enterprises and small enterprises 	6.79	4.62	
	 Total outstanding dues of creditors other than micro enterprises and small enterprises 	30.38	27.22	
	(iii) Other Financial Liabilities	14.59	20.28	
	(b) Other Current Liabilities	6.09	5.19	
	(c) Provisions	1.28	1.29	
	(d) Current tax liabilities (net)	3.05	2.20	
	Total Current Liabilities	86.18	80.77	
	Total Liabilities(4+5)	384.79	338.61	
	Total Equity and Liabilities(3+4+5)	568.83	495.76	

Notes:

- 1 The above unaudited financial results of Dr. Agarwal's Eye Hospital Limited ("the Company") for the quarter and six months ended 30th September 2024 are prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2 The above unaudited financial results have been reviewed by the Audit Committee and the same has been approved and taken on record by the Board of Directors at their meeting held on 29th October 2024. The above results for the quarter ended and six months ended 30th September 2024 has been subjected to Limited review by Statutory auditors of the Company.
- The Company operates in a single segment i.e. "Eye Care related sales and services" and does not have any additional disclosures to be made under Ind AS 108 Operating Segments.
- 4 Figures for the previous periods, have been regrouped/ reclassified, wherever necessary, to conform to the current period's presentation.
- The Company declared an interim dividend of Rs. 2.5 per equity share of Rs. 10/- each pursuant to the approval of the board of directors, at their meeting held on 29th October 2024.

CHENNAI-17

Date: 29th October 2024

Chennai de Chennai de

By order of the Board

Dr. Amar Agarwal
Chairman & Managing Director
DIN 00435684

Dr Agarwals Eye Hospital

Dr. Agarwal's Eye Hospital Limited
CIN: L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No. 4, Moores Road, Off Greams Road, Chennai - 600 006
Phone No. 91-44-43787777 Website: www.dragarwal.com E-mail: investor@dragarwal.com

(Amount in INR Crores)

	Cash flow Statement						
	Particulars	For the Six Months Ended 30th September 2024	For the Six Months Ended 30th September 2023				
Α.	CASH FLOW FROM OPERATING ACTIVITIES						
	Profit before tax for the period	38.04	32.19				
	Adjusted for:	2.37.5.7					
	(Profit)/ loss on sale/ discard of property, plant and equipment and other	0.01	(0,19)				
	intangible assets (net)	0.01	(0,19)				
	Allowances for expected credit loss (including bad debts written off)	0.85	(0.06)				
	Interest on acquisition liability	0.41	0.09				
	Depreciation and amortisation expense	19.23	12.19				
	Liabilities/ provisions no longer required written back	(1.58)	19.0				
	Profit on redemption of current investments (including net gain / (loss) arising on financial assets designated as fair value through profit and loss)	(0.51)	8.				
	Interest income	(0.40)	(0.77)				
	Finance costs (excludes Interest on acquisition liability)	6.29	3.22				
	Operating profit before working capital and other changes	62.34	46.67				
	operating profit actions of capital and calls are also						
	Adjustments for (increase)/decrease in operating assets:		42,424				
	Inventories	(2.05)	(2.04)				
	Trade receivables	(4.17)	0.37				
	Other financial assets - Non current	(0.81)	0.15				
	Other financial assets - Current	(0.57)	(0.13)				
	Other current assets	(0.51)	(0,99)				
	Adjustments for increase/(decrease) in operating liabilities:	(2.05)	6,19				
	Trade payables Other financial liabilities - Non current	(2.05)	0.95				
	Other financial liabilities - Current	(4.46)	2,72				
	Provisions	0.92	1.24				
	Other current liabilities	0.93	0.41				
	Cash generated from operations	50.24	55.54				
	Income Taxes paid (net of refunds)	(9.09)	(8.80)				
	Net cash generated from operating activities (A)	41.15	46.74				
В.	CASH FLOW FROM INVESTING ACTIVITIES						
D.	Capital expenditure towards tangible assets (including capital advances, net of capital creditors)	(39.63)	(25.21)				
	Proceeds from Sale of Property, Plant and Equipment	0.02	0.38				
	Capital expenditure towards intangible assets	(1.40)					
	Payment towards acquisition of Business (including acquisition liabilities	(18.48)	(0.45)				
	paid) Increase/(Decrease) in Bank balances not considered as Cash and cash equivalents	0.05	(0,04)				
	Interest Received on Fixed Deposit	0.05	0.84				
	Purchase of investments	(51.05)	-				
	Sale of Investments	38.07	•				
	Net cash (used in) investing activities (B)	(72.37)	(24.48)				
C.	CASH FLOW FROM FINANCING ACTIVITIES						
	Proceeds from Borrowings	31.51	(4.57)				
	Repayment of Borrowings	(6.70)					
	Dividend paid (including tax thereon)	(1.19)	**				
	Finance costs paid on borrowings	(0.49)	(0.20)				
	Payment of lease liabilities	(10.64)	(8.18)				
	Net cash generated from/ (used in) financing activities (C)	12.49	(12.95)				





Dr Agarwals

Dr. Agarwal's Eye Hospital Limited
CIN: L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No. 4, Moores Road, Off Greams Road, Chennai - 600 006 Phone No. 91-44-43787777 Website: www.dragarwal.com E-mail: investor@dragarwal.com

(Amount in INR Crores)

Cash flow Statement			
Particulars	For the Six Months Ended 30th September 2024	For the Six Months Ended 30th Septembe 2023	
Net (Decrease) / Increase in Cash and Cash Equivalents (A+B+C) = (D)	(18.73)	9.31	
Cash and cash equivalents at the beginning of the period (E)	32.88	27.38	
Cash and cash equivalents at the end of the period (D + E) = (F)	14.15	36.69	
Cash on hand	0,79	0.51	
Balances with Banks	13,36	36.18	
Cash and cash equivalents at the end of the period	14.15	36.69	

Place : Chennai

Date: 29th October 2024

By order of the Board

Dr. Amar Agarwal Chairman & Managing Director DIN 00435684



Dr. Agarwal's Eye Hospital Limited CIN: L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No. 4, Moores Road, Off Greams Road, Chennai - 600 006
Phone No. 91-44-43787777 Website: www.dragarwal.com E-mail: investor@dragarwal.com

(Amount in INR Crores except EPS)

Statement of Unaudited Financial Resu	Its for the Quarte	r and Six Months	Ended 30th Sept	tember 2024		
		Quarter Ended		Six Mont	Six Months Ended	
Particulars Particulars	30-Sep-24 (Unaudited)	30-Jun-24 (Unaudited)	30-Sep-23 (Unaudited)	30-Sep-24 (Unaudited)	30-Sep-23 (Unaudited)	31-Mar-24 (Audited)
Revenue from Operations	102.19	100.02	84.09	202.21	162.64	319.30
Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	19.13	18,91	16.65	38.04	32.19	62.25
Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	19.13	18.91	16,65	38.04	32.19	62.25
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	14.15	14.11	12.59	28.26	24.13	46.36
Total Comprehensive Income / (Loss) for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	13.94	14.13	12.20	28.07	23,65	46.40
Paid -up Equity Share Capital (Face Value of INR 10/- each)	4.70	4.70	4.70	4.70	4.70	4.70
Reserves (Other Equity)						152.45
Earnings Per Share (for continuing and discontinued operations) (Face Value of INR 10/- each):						
(a) Basic	30.11	30.02	26.79	60.13	51.34	98.64
(b) Diluted	30.11	30.02	26.79	60.13	51.34	98.64
	(not Annualised)	(Annualised)				

Notes:

1) The above is an extract of the detailed format of Annual Audited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Annual Audited Financial Results is available on the Stock Exchange website (www.bseindia.com) and on the Company's website (www.dragarwal.com).

Place : Chennai

Date: 29th October 2024

Dr. Amar Agarwal Chairman & Managing Director DIN 00435684